Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer

Tomohisa Otsu, Yoshikuni Inokawa^*, Hideki Takami, Masamichi Hayashi, Keisuke Kurimoto, Nobutake Tanaka, Haruyoshi Tanaka, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Yasuhiro Kodera